BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI)

Historical Holders from Q1 2018 to Q2 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Symbol: BTAI on Nasdaq
Shares outstanding: 6,235,531
Price per share: $0.3699

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Qatar Investment Authority	5.2%		$463,093		2,724,075		Qatar Investment Authority	25 Nov 2024
Oaktree Capital Group Holdings GP, LLC	2.7%	-49%	$28,939	-$434,154	170,230	-94%	Oaktree Capital Holdings, LLC	31 Mar 2025

Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (% of par)	Investors
2025 Q2	14,875	$5,503	+$5,503			36.99%	1
2025 Q1	0	$0	-$3,224,068	$0	$0		0
2024 Q4	8,627,682	$3,224,936	+$2,041,377	$22,210	$12,900	37.39%	47
2024 Q3	3,099,756	$1,890,127	-$7,944,274	$24,522	$13,542	61%	46
2024 Q2	9,738,748	$12,466,903	-$1,711,528	$262,954	$129,152	128%	71
2024 Q1	9,238,957	$26,053,732	-$415,412	$624,603	$239,700	282%	71
2023 Q4	9,351,765	$27,595,077	-$1,941,847	$966,519	$238,950	295%	72
2023 Q3	10,142,059	$25,655,976	-$27,908,890	$550,781	$928,763	253%	82
2023 Q2	17,642,933	$117,491,802	-$7,226,324	$3,935,434	$3,112,218	666%	83
2023 Q1	17,417,079	$324,965,795	+$71,330,482	$3,286,026	$4,898,250	1,866%	96
2022 Q4	13,442,183	$288,837,441	+$37,768,271	$1,250,136	$2,788,104	2,148%	81
2022 Q3	11,865,502	$140,259,937	-$11,714,266	$820,000	$1,831,000	1,182%	82
2022 Q2	12,674,614	$167,321,205	-$8,492,233	$1,592,000	$1,846,000	1,319.99%	90
2022 Q1	13,111,117	$273,902,967	-$16,331,751	$4,063,000	$3,230,000	2,090.79%	93
2021 Q4	13,927,053	$283,060,517	+$19,228,913	$2,596,000	$3,108,000	2,032.88%	90
2021 Q3	12,791,796	$388,253,110	-$6,408,094	$6,152,000	$6,161,000	3,035%	103
2021 Q2	13,030,148	$378,637,038	+$41,282,735	$7,322,000	$4,501,000	2,905.93%	108
2021 Q1	11,015,188	$475,171,234	-$56,530,789	$9,456,000	$10,301,000	4,315.93%	114
2020 Q4	12,260,234	$566,451,752	+$16,958,479	$11,102,000	$26,762,000	4,620%	114
2020 Q3	11,873,463	$514,719,363	+$152,548,583	$6,024,000	$21,530,000	4,335.87%	107
2020 Q2	8,121,087	$430,587,215	+$116,997,084	$11,788,000	$24,304,000	5,300.98%	103
2020 Q1	5,997,060	$133,825,071	+$39,824,964	$1,933,000	$3,956,000	2,234.99%	68
2019 Q4	4,342,692	$63,268,018	+$1,450,806			1,460.99%	42
2019 Q3	4,179,707	$29,412,098	+$8,120,529			703.92%	41
2019 Q2	2,932,356	$32,048,175	+$4,610,881			1,095.5%	34
2019 Q1	2,512,687	$24,935,000	+$931,694			989.11%	19
2018 Q4	2,420,717	$9,354,000	-$3,409,943			385.44%	11
2018 Q3	3,251,790	$24,996,000	-$3,807,303			765.96%	17
2018 Q2	3,723,565	$34,207,000	-$9,901,055			919.89%	19
2018 Q1	4,695,186	$47,920,000	+$47,920,000			1,023.73%	22